Clinical trial
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese…
NCT00479076 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00479076 |
|---|---|
| Title | A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients |
| Official title | A Single Agent-combination Hybrid Phase I, Open-label, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous AVE0005 (VEGF Trap)Administered Every 2 Weeks in Combination With Oral S-1 in Patients With Advanced Solid Malignancies |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Regeneron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | aflibercept (AVE0005), S-1 |
| Enrollment | 22 |
| Start date | Mar 1, 2007 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | May 25, 2007 |
| Last update posted | Jan 26, 2011 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: